XS005 Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)
The main objective of this clinical study is to evaluate the safety of XS005 injection; to determine the maximum tolerated dose . Furthermore, initial efficacy will be examined.
Tumor
BIOLOGICAL: XS005 Injection
Incidence of Dose-Limiting Toxicities (DLTs), DLT is defined as a toxic effect in the subject at any dose, cannot be reasonably attributed to the subject's underlying disease, other conditions, and/or concomitants, that the investigator determines to be related (including definitely, likely, or possibly) to the XS005 injection., within 7 days after the the first infusion of XS005.|Incidence of Adverse Events (AEs), AE is defined as any adverse medical event within 4 months after the the first infusion of XS005., 4 months|Maximum tolerated dose (MTD), MTD is defined as the highest dose level of less than or equal to 2 DLT among the 6 subjects finally determined., within 7 days after the the first infusion of XS005.
Progression-free survival (PFS), PFS : defined as the time from the start of treatment until the onset of tumor progression or death from any cause;, From the start of treatment until the time of first disease progression or death , assessed up to 12 months post-treatment
Treatment on this study includes eight XS005 infusions over an 16 week period. The study will evaluate the safety, feasibility and maximum tolerated dose (MTD) of XS005 using a 3+3 study design . The total study duration will be 2 years.